Expression of 14-3-3-zeta in patients with stage Ⅲ/Ⅳ mantle cell lymphoma and its clinical significance
Received:May 23, 2016  Revised:August 21, 2016
View Full Text  View/Add Comment  Download reader
Key words:14-3-3zeta protein  lymphoma, mantle cell  prognosis
Author NameAffiliationE-mail
ZHU Mi-Na1, WANG Jian-Hong2, HAO Cai-Xia2, WANG Wen-Yong3, ZHANG Na2, JIA Wei-Jing2, TANG Hai-Long2, DONG Bao-Xia2, GU Hong-Tao2, ZHANG Tao2, YANG Lan2, GAO Guang-Xun2, CHEN Xie-Qun2, WANG Zhe3, LIANG Rong2* 1Department of Emergency, Xi’an No.1 Hospital, Xi’an 710002, China
2Department of Hematology, 3Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China 
Hits: 1831
Download times: 950
      Objective To investigate the relationships of 14-3-3zeta protein expression with the therapeutic efficacy and prognosis of the patients with mantle cell lymphoma (MCL). Methods Clinical data of 12 MCL patients who were confirmed pathologically and treated in the Department of Hematology of Xijing Hospital between March 2007 and March 2012 were collected and analyzed. The protein expression of 14-3-3zeta in the patients was detected immunohistochemically, and its correlation with the prognosis of the patients was analyzed. Results Compared with reactive lymphoid hyperplasia, 8 cases showed positive expression of 14-3-3zeta in the cytoplasm, accounting for 66.7%. The overall response rate (ORR), and 2-year overall survival (OS) and 2-year progression-free survival (PFS) were 62.5%,50.0% and 37.5% respectively in the patients with positive expression of 14-3-3zeta, significantly lower than those in the negative expression patients (75.0%, 100.0 and 75.0%). Our results need in-depth study with larger samples. Conclusion MCL patients have abnormally high expression of 14-3-3zeta protein, and its expression level may be correlated with the patients’prognosis.